The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | CAPTIVATE: 1-year DFS results from the MRD cohort in CLL
William Wierda, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines 1-year disease-free survival (DFS) results from the minimal residual disease (MRD) cohort of the Phase II CAPTIVATE study (NCT02910583) investigating ibrutinib plus venetoclax for first-line treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia. The 1-year DFS in patients received to placebo after ibrutinib plus venetoclax treatment was similar to that of patients continuing ibrutinib, supporting a fixed-duration treatment. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
